Zhaoke Ophthalmology Ltd. (HK:6622) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zhaoke Ophthalmology Ltd. has announced that China’s National Medical Products Administration has accepted their abbreviated new drug application for NVK002, an investigational treatment for myopia progression in children. Following successful Phase III trials showing significant safety and efficacy, NVK002 is positioned as one of the leading treatments in tackling the myopia epidemic affecting millions of children in China. This development could establish Zhaoke Ophthalmology as a key player in addressing unmet needs in the Chinese ophthalmic market.
For further insights into HK:6622 stock, check out TipRanks’ Stock Analysis page.